TD Private Client Wealth LLC Boosts Stake in DaVita Inc. (NYSE:DVA)

TD Private Client Wealth LLC raised its holdings in DaVita Inc. (NYSE:DVA) by 1,483.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,688 shares of the company’s stock after acquiring an additional 4,392 shares during the period. TD Private Client Wealth LLC’s holdings in DaVita were worth $701,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Amundi lifted its holdings in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after acquiring an additional 240,126 shares during the last quarter. KBC Group NV grew its position in DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after acquiring an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets increased its stake in DaVita by 23.9% in the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after acquiring an additional 56,389 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after purchasing an additional 12,339 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the topic of several recent research reports. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays boosted their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Finally, StockNews.com lowered shares of DaVita from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Stock Down 0.5 %

Shares of DaVita stock opened at $148.25 on Monday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The company’s 50 day moving average price is $158.53 and its 200-day moving average price is $157.56. The stock has a market capitalization of $11.86 billion, a price-to-earnings ratio of 13.80, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.